title: Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.
abstract: The primary objective of this study was to determine the response rate of patients with metastatic colorectal cancer to combined therapy with 5-fluorouracil (5-FU), leucovorin, and intravenous azidothymidine (AZT), a thymidine nucleoside analog. By itself, AZT has limited antineoplastic efficacy. However, experimental studies indicate that 5-FU enhances the antitumor activity of AZT by inhibiting synthesis of normal thymidine nucleotides with which AZT competes for incorporation into nucleic acids. A phase I study defined the maximum tolerated dose of AZT as 7 g/m2 with hypotension during the infusion being the dose-limiting toxicity. A phase II study was performed with oral leucovorin (100 mg p.o. hourly for 4 h prior to 5-FU and 4 h and 8 h after 5-FU), bolus 5-FU (400 mg/m2) followed 1 h later by a 2-h infusion of AZT (7 g/m2). Treatment was given weekly for 4 weeks followed by a 1-week break, which constituted a cycle of therapy. Responses were evaluated after every two cycles. Patients continued on therapy as long as they tolerated treatment and did not have progressive disease. Of 15 evaluable patients who had received no chemotherapy there was 1 complete response and 4 partial responses (a 33% response rate), whereas only 1 of 6 patients who had received prior adjuvant chemotherapy had a partial response (17%). An additional 10 patients had stable disease lasting 2-14 months. Therapy was well tolerated with the only one instance each of grade 3 nausea and vomiting, diarrhea, anemia, and hypotension. Approximately 50% of treatments were accompanied by mild hypotension, which was easily corrected by increasing the rate of normal saline infusion. There was no difficulty administering this regimen in the outpatient setting. While the overall response rate (29%) is comparable to that seen with combinations of 5-FU and leucovorin alone, in most reported series a considerably higher dose of 5-FU was utilized than in this study. Since patients in the present study experienced relatively little 5-FU toxicity, increasing the dose of 5-FU in this regimen would appear to be feasible and might result in a higher response rate.
authors.affiliation: Brown University Clinical Oncology Group, Providence, RI 02908, USA.
authors.forename: J
authors.initials: J
authors.lastname: Clark
authors.forename: W
authors.initials: W
authors.lastname: Sikov
authors.forename: F
authors.initials: F
authors.lastname: Cummings
authors.forename: M
authors.initials: M
authors.lastname: Browne
authors.forename: W
authors.initials: W
authors.lastname: Akerley
authors.forename: H
authors.initials: H
authors.lastname: Wanebo
authors.forename: A
authors.initials: A
authors.lastname: Weitberg
authors.forename: T
authors.initials: T
authors.lastname: Kennedy
authors.forename: B
authors.initials: B
authors.lastname: Cole
authors.forename: J
authors.initials: J
authors.lastname: Bigley
authors.forename: J
authors.initials: J
authors.lastname: Beitz
authors.forename: J
authors.initials: J
authors.lastname: Darnowski
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008297:Male; D008875:Middle Aged; D015215:Zidovudine / Q000008:administration & dosage
chemical_list: D015215:Zidovudine; D002955:Leucovorin; D005472:Fluorouracil